SCCR32: KEI, EIFL and FIM comments on GRULAC Papers
Search Results for: ustr
April 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patents
Senator Hatch, before pressuring Colombia over cancer drug compulsory license, wanted one for Napster
(More on Colombia here: /colombia)
Continue Reading
2016: Dedalus Pharma, LLC, KEI comments on NIH proposal for exclusive licenses on CARs to treat cancer
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On April 22nd, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dedalus… Continue Reading
Rep. Lloyd Doggett keynote address at CAP drug pricing event highlights Xtandi, federal funding of pharmaceutical R&D
On April 26, 2016, Congressman Lloyd Doggett (D-Texas) delivered the keynote address at a panel discussion on drug pricing at the Center for American Progress, where he addressed the Federal government’s role in subsidizing drug development, ensuring affordable access at reasonable prices for U.S. citizens, industry practices related to monopoly pricing, and legislative solutions to promote rational and affordable drug prices.
Transparency of patents on medicines and other technologies
2016:1 KEI Briefing Note
Transparency of Patent Landscapes
April 25, 2016
At an April 12, 2016 WIPO seminar, Reed F. Beall and Amir Attaran presented a paper, “Patent-based Analysis of the World Health Organization’s 2013 Model List of Essential Medicines,” which includes the following odd comment:
WHO releases program of work and progress report in advance of Consultative Expert Working Group on R&D (2-4 May 2016)
The World Health Organization (WHO) is convening an open-ended meeting of member states on the Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) in Geneva, Switzerland at WHO headquarters from 2 May 2016 to 4 May 2016. The WHO has published the provisional agenda, the proposed program of work and progress report. Continue Reading
RCEP: Regional Comprehensive Economic Partnership
2015 Oct 16 version: RCEP draft text for investment chapter
(More KEI RCEP leaks here: /rcep)
Attached below is the October 16, 2015 version of the investment chapter for the proposed Regional Comprehensive Economic Partnership, known as RCEP. This text is made public for the first time by KEI.
Letter to HHS and NIH regarding impact of high prices on cost effectiveness of Xtandi
KEI submitted the attached letter to Secretary Burwell and Director Collins in support of the KEI/UACT petition that asked the NIH (or the Army) to use the federal government rights in the patents on the prostate cancer drug Xtandi, to remedy the excessive and discriminatory price in the United States. The letter calls attention to findings of an article from the the Journal of Oncology Pharmacy Practice, in which the authors conclude that a reduction in price would make Xtandi the most-cost effective option.
The text of the letter follows: